Cargando…
TR-FRET-Based Immunoassay to Measure Ataxin-2 as a Target Engagement Marker in Spinocerebellar Ataxia Type 2
Spinocerebellar ataxia type 2 (SCA2) is an autosomal dominantly inherited neurodegenerative disease, which belongs to the trinucleotide repeat disease group with a CAG repeat expansion in exon 1 of the ATXN2 gene resulting in an ataxin-2 protein with an expanded polyglutamine (polyQ)-stretch. The di...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122633/ https://www.ncbi.nlm.nih.gov/pubmed/36894829 http://dx.doi.org/10.1007/s12035-023-03294-y |
_version_ | 1785029534275338240 |
---|---|
author | Bux, Jessica Sen, Nesli Ece Klink, Isa-Maria Hauser, Stefan Synofzik, Matthis Schöls, Ludger Auburger, Georg Riess, Olaf Hübener-Schmid, Jeannette |
author_facet | Bux, Jessica Sen, Nesli Ece Klink, Isa-Maria Hauser, Stefan Synofzik, Matthis Schöls, Ludger Auburger, Georg Riess, Olaf Hübener-Schmid, Jeannette |
author_sort | Bux, Jessica |
collection | PubMed |
description | Spinocerebellar ataxia type 2 (SCA2) is an autosomal dominantly inherited neurodegenerative disease, which belongs to the trinucleotide repeat disease group with a CAG repeat expansion in exon 1 of the ATXN2 gene resulting in an ataxin-2 protein with an expanded polyglutamine (polyQ)-stretch. The disease is late manifesting leading to early death. Today, therapeutic interventions to cure the disease or even to decelerate disease progression are not available yet. Furthermore, primary readout parameter for disease progression and therapeutic intervention studies are limited. Thus, there is an urgent need for quantifiable molecular biomarkers such as ataxin-2 becoming even more important due to numerous potential protein-lowering therapeutic intervention strategies. The aim of this study was to establish a sensitive technique to measure the amount of soluble polyQ-expanded ataxin-2 in human biofluids to evaluate ataxin-2 protein levels as prognostic and/or therapeutic biomarker in SCA2. Time-resolved fluorescence energy transfer (TR-FRET) was used to establish a polyQ-expanded ataxin-2-specific immunoassay. Two different ataxin-2 antibodies and two different polyQ-binding antibodies were validated in three different concentrations and tested in cellular and animal tissue as well as in human cell lines, comparing different buffer conditions to evaluate the best assay conditions. We established a TR-FRET-based immunoassay for soluble polyQ-expanded ataxin-2 and validated measurements in human cell lines including iPSC-derived cortical neurons. Additionally, our immunoassay was sensitive enough to monitor small ataxin-2 expression changes by siRNA or starvation treatment. We successfully established the first sensitive ataxin-2 immunoassay to measure specifically soluble polyQ-expanded ataxin-2 in human biomaterials. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12035-023-03294-y. |
format | Online Article Text |
id | pubmed-10122633 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-101226332023-04-24 TR-FRET-Based Immunoassay to Measure Ataxin-2 as a Target Engagement Marker in Spinocerebellar Ataxia Type 2 Bux, Jessica Sen, Nesli Ece Klink, Isa-Maria Hauser, Stefan Synofzik, Matthis Schöls, Ludger Auburger, Georg Riess, Olaf Hübener-Schmid, Jeannette Mol Neurobiol Article Spinocerebellar ataxia type 2 (SCA2) is an autosomal dominantly inherited neurodegenerative disease, which belongs to the trinucleotide repeat disease group with a CAG repeat expansion in exon 1 of the ATXN2 gene resulting in an ataxin-2 protein with an expanded polyglutamine (polyQ)-stretch. The disease is late manifesting leading to early death. Today, therapeutic interventions to cure the disease or even to decelerate disease progression are not available yet. Furthermore, primary readout parameter for disease progression and therapeutic intervention studies are limited. Thus, there is an urgent need for quantifiable molecular biomarkers such as ataxin-2 becoming even more important due to numerous potential protein-lowering therapeutic intervention strategies. The aim of this study was to establish a sensitive technique to measure the amount of soluble polyQ-expanded ataxin-2 in human biofluids to evaluate ataxin-2 protein levels as prognostic and/or therapeutic biomarker in SCA2. Time-resolved fluorescence energy transfer (TR-FRET) was used to establish a polyQ-expanded ataxin-2-specific immunoassay. Two different ataxin-2 antibodies and two different polyQ-binding antibodies were validated in three different concentrations and tested in cellular and animal tissue as well as in human cell lines, comparing different buffer conditions to evaluate the best assay conditions. We established a TR-FRET-based immunoassay for soluble polyQ-expanded ataxin-2 and validated measurements in human cell lines including iPSC-derived cortical neurons. Additionally, our immunoassay was sensitive enough to monitor small ataxin-2 expression changes by siRNA or starvation treatment. We successfully established the first sensitive ataxin-2 immunoassay to measure specifically soluble polyQ-expanded ataxin-2 in human biomaterials. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12035-023-03294-y. Springer US 2023-03-09 2023 /pmc/articles/PMC10122633/ /pubmed/36894829 http://dx.doi.org/10.1007/s12035-023-03294-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Bux, Jessica Sen, Nesli Ece Klink, Isa-Maria Hauser, Stefan Synofzik, Matthis Schöls, Ludger Auburger, Georg Riess, Olaf Hübener-Schmid, Jeannette TR-FRET-Based Immunoassay to Measure Ataxin-2 as a Target Engagement Marker in Spinocerebellar Ataxia Type 2 |
title | TR-FRET-Based Immunoassay to Measure Ataxin-2 as a Target Engagement Marker in Spinocerebellar Ataxia Type 2 |
title_full | TR-FRET-Based Immunoassay to Measure Ataxin-2 as a Target Engagement Marker in Spinocerebellar Ataxia Type 2 |
title_fullStr | TR-FRET-Based Immunoassay to Measure Ataxin-2 as a Target Engagement Marker in Spinocerebellar Ataxia Type 2 |
title_full_unstemmed | TR-FRET-Based Immunoassay to Measure Ataxin-2 as a Target Engagement Marker in Spinocerebellar Ataxia Type 2 |
title_short | TR-FRET-Based Immunoassay to Measure Ataxin-2 as a Target Engagement Marker in Spinocerebellar Ataxia Type 2 |
title_sort | tr-fret-based immunoassay to measure ataxin-2 as a target engagement marker in spinocerebellar ataxia type 2 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122633/ https://www.ncbi.nlm.nih.gov/pubmed/36894829 http://dx.doi.org/10.1007/s12035-023-03294-y |
work_keys_str_mv | AT buxjessica trfretbasedimmunoassaytomeasureataxin2asatargetengagementmarkerinspinocerebellarataxiatype2 AT sennesliece trfretbasedimmunoassaytomeasureataxin2asatargetengagementmarkerinspinocerebellarataxiatype2 AT klinkisamaria trfretbasedimmunoassaytomeasureataxin2asatargetengagementmarkerinspinocerebellarataxiatype2 AT hauserstefan trfretbasedimmunoassaytomeasureataxin2asatargetengagementmarkerinspinocerebellarataxiatype2 AT synofzikmatthis trfretbasedimmunoassaytomeasureataxin2asatargetengagementmarkerinspinocerebellarataxiatype2 AT scholsludger trfretbasedimmunoassaytomeasureataxin2asatargetengagementmarkerinspinocerebellarataxiatype2 AT auburgergeorg trfretbasedimmunoassaytomeasureataxin2asatargetengagementmarkerinspinocerebellarataxiatype2 AT riessolaf trfretbasedimmunoassaytomeasureataxin2asatargetengagementmarkerinspinocerebellarataxiatype2 AT hubenerschmidjeannette trfretbasedimmunoassaytomeasureataxin2asatargetengagementmarkerinspinocerebellarataxiatype2 |